

GRIFOLS

KEY FIGURES FY 2024

Financial metrics

Revenues

FY24	Q4'24
€ 7,212M	€ 1,976M
+10.3% cc	+13.6% cc

Adjusted EBITDA

FY24	Q4'24
€ 1,779M	€ 526M
+21.7%	+18.6%

Adjusted EBITDA Margin

FY24	Q4'24
24.7%	26.6%
+250bps	+150bps

Leverage ratio

FY24	FY23
4.6x	6.4x
4.5X cc	

Free Cash Flow

FY24	Q4'24
€ 266M	€ 335M
+€442M	+€326M

Conclusions




All-time-high revenue



Growth across all business units, led by Biopharma



Profitability expansion driven by revenues growth, operational efficiencies and cost discipline



Strong Free Cash Flow Generation far exceeding guidance



Progressing on our deleveraging path throughout the year



Strengthened balance sheet through SRAAS asset sale and debt refinancing, while enhancing liquidity